0.40
price down icon8.47%   -0.037
after-market 시간 외 거래: .40
loading
전일 마감가:
$0.437
열려 있는:
$0.425
하루 거래량:
342.95K
Relative Volume:
2.89
시가총액:
$12.24M
수익:
-
순이익/손실:
$-58.52M
주가수익비율:
-0.1914
EPS:
-2.09
순현금흐름:
$-45.03M
1주 성능:
-24.74%
1개월 성능:
-48.65%
6개월 성능:
-69.92%
1년 성능:
-83.94%
1일 변동 폭
Value
$0.3518
$0.4664
1주일 범위
Value
$0.3518
$0.5699
52주 변동 폭
Value
$0.3518
$2.49

Nextcure Inc Stock (NXTC) Company Profile

Name
명칭
Nextcure Inc
Name
전화
240-399-4900
Name
주소
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Name
직원
43
Name
트위터
@nextcureinc
Name
다음 수익 날짜
2025-03-07
Name
최신 SEC 제출 서류
Name
NXTC's Discussions on Twitter

NXTC을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
NXTC
Nextcure Inc
0.40 12.24M 0 -58.52M -45.03M -2.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
483.49 124.48B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
625.60 67.45B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
583.62 35.60B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
266.83 34.53B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
274.78 29.15B 3.81B -644.79M -669.77M -6.24

Nextcure Inc Stock (NXTC) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2022-11-04 다운그레이드 Ladenburg Thalmann Buy → Neutral
2022-03-01 개시 Ladenburg Thalmann Buy
2021-03-05 업그레이드 Truist Hold → Buy
2021-01-15 다운그레이드 BofA Securities Neutral → Underperform
2020-07-16 업그레이드 The Benchmark Company Hold → Buy
2020-07-13 다운그레이드 ROTH Capital Buy → Neutral
2020-07-13 다운그레이드 SunTrust Buy → Hold
2020-06-01 다운그레이드 BofA/Merrill Buy → Neutral
2020-06-01 다운그레이드 The Benchmark Company Buy → Hold
2020-05-26 개시 JMP Securities Mkt Outperform
2020-03-24 개시 The Benchmark Company Buy
2020-03-02 개시 ROTH Capital Buy
2020-01-13 개시 SunTrust Buy
2019-12-05 개시 Needham Buy
2019-11-26 개시 BTIG Research Buy
2019-07-09 개시 BofA/Merrill Buy
2019-06-03 개시 Morgan Stanley Overweight
2019-06-03 개시 Piper Jaffray Overweight
모두보기

Nextcure Inc 주식(NXTC)의 최신 뉴스

pulisher
Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 - Investing.com India

Apr 01, 2025
pulisher
Apr 01, 2025

NextCure stock plunges to 52-week low, hits $0.46 By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

NextCure stock hits 52-week low at $0.55 amid market challenges - Investing.com India

Mar 25, 2025
pulisher
Mar 19, 2025

12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga

Mar 19, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock - Investing.com India

Mar 18, 2025
pulisher
Mar 18, 2025

H.C. Wainwright maintains Buy rating, $3 target on NextCure stock By Investing.com - Investing.com South Africa

Mar 18, 2025
pulisher
Mar 18, 2025

NextCure’s (NXTC) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 18, 2025
pulisher
Mar 17, 2025

NextCure stock plunges to 52-week low at $0.66 amid market challenges - Investing.com Australia

Mar 17, 2025
pulisher
Mar 13, 2025

NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday - Defense World

Mar 13, 2025
pulisher
Mar 10, 2025

2 Net Current Asset Value Stocks to Consider - GuruFocus.com

Mar 10, 2025
pulisher
Mar 08, 2025

Nextcure Faces Delisting Risk Amid Nasdaq Compliance Struggles - MSN

Mar 08, 2025
pulisher
Mar 07, 2025

NextCure Reports 2024 Financials and Strategic Progress - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

NextCure Provides Business Update and Reports Full Year 2024 Financial Results - The Manila Times

Mar 07, 2025
pulisher
Mar 06, 2025

NextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill Cohorts - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Can NextCure's $68M Cash Support Its Cancer Drug Development Through 2026? - StockTitan

Mar 06, 2025
pulisher
Feb 27, 2025

Korea Biotech Roundup: Orum, DongKook Price IPOs Below Band - insights.citeline.com

Feb 27, 2025
pulisher
Feb 27, 2025

NextCure stock plunges to 52-week low, hits $0.69 - MSN

Feb 27, 2025
pulisher
Feb 12, 2025

NextCure stock plunges to 52-week low, hits $0.69 By Investing.com - Investing.com Canada

Feb 12, 2025
pulisher
Feb 10, 2025

Ventia Strengthens Leadership with New Company Secretary Appointment - MSN

Feb 10, 2025
pulisher
Feb 10, 2025

Is NextCure (NASDAQ:NXTC) In A Good Position To Invest In Growth? - Yahoo Finance

Feb 10, 2025
pulisher
Feb 06, 2025

Eaton Vance Tax-Managed Diversified Equity Income Fund declares $0.0992 dividend - MSN

Feb 06, 2025
pulisher
Feb 04, 2025

NextCure Faces Potential Delisting from Nasdaq Global Select Market Due to Minimum Bid Requirement Non-Compliance - Defense World

Feb 04, 2025
pulisher
Jan 24, 2025

12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga

Jan 24, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Acquires 27,812 Shares of NextCure, Inc. (NASDAQ:NXTC) - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Jane Street Group LLC Has $125,000 Holdings in Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA) - Defense World

Jan 14, 2025
pulisher
Jan 13, 2025

NextCure Initiates Phase 1 Study for B7-H4 ADC Therapy to Treat Multiple Cancers_ - Defense World

Jan 13, 2025
pulisher
Jan 12, 2025

LigaChem Biosciences doses first patient in phase 1 trial of LNCB74 cancer drugCHOSUNBIZ - 조선비즈

Jan 12, 2025
pulisher
Jan 10, 2025

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 as Therapeutic for Treating Multiple Cancers - Marketscreener.com

Jan 10, 2025
pulisher
Jan 10, 2025

NextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple Cancers - The Manila Times

Jan 10, 2025
pulisher
Jan 10, 2025

NextCure Advances Cancer Treatment: First Patient Dosed in LNCB74 Phase 1 Trial - StockTitan

Jan 10, 2025
pulisher
Jan 07, 2025

Pre-market Movers: CDT, NARI, GDTC, NARI... - RTTNews

Jan 07, 2025
pulisher
Dec 25, 2024

NextCure stock hits 52-week low at $0.87 amid market challenges - Investing.com Australia

Dec 25, 2024
pulisher
Dec 25, 2024

NextCure stock hits 52-week low at $0.87 amid market challenges By Investing.com - Investing.com South Africa

Dec 25, 2024
pulisher
Dec 17, 2024

NextCure stock hits 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa

Dec 17, 2024
pulisher
Dec 16, 2024

NextCure stock hits 52-week low at $0.99 amid market challenges - Investing.com India

Dec 16, 2024
pulisher
Dec 12, 2024

The Buckle, Inc. Announces Dividend PayoutsKearney, NE — The Buckle, Inc. (NYSE: BKE) disclosed plans for upcoming shareholder dividend payments following the quarterly meeting of its Board of Directors on December 9, 2024. The company greenlighte - Defense World

Dec 12, 2024
pulisher
Dec 11, 2024

FDA clears IND for B7-H4-targeting ADC - BioWorld Online

Dec 11, 2024
pulisher
Dec 10, 2024

NextCure Announces Acceptance of IND Application for LNCB74 - The Manila Times

Dec 10, 2024
pulisher
Dec 10, 2024

NextCure, Inc. Announces Acceptance of IND Application for LNCB74 - Marketscreener.com

Dec 10, 2024
pulisher
Dec 10, 2024

NextCure's Cancer Drug LNCB74 Secures FDA IND Approval for Phase 1 Clinical Trials - StockTitan

Dec 10, 2024
pulisher
Dec 07, 2024

NextCure stock hits 52-week low at $1.00 amid market challenges - Investing.com Australia

Dec 07, 2024
pulisher
Dec 06, 2024

NextCure stock hits 52-week low at $1.00 amid market challenges By Investing.com - Investing.com South Africa

Dec 06, 2024

Nextcure Inc (NXTC) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$73.44
price up icon 2.00%
$68.32
price up icon 0.56%
$31.28
price up icon 0.35%
$20.46
price up icon 8.83%
$93.32
price up icon 3.36%
biotechnology ONC
$274.78
price up icon 1.38%
자본화:     |  볼륨(24시간):